|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
135,340,000 |
Market
Cap: |
650.99(M) |
Last
Volume: |
11,363,101 |
Avg
Vol: |
11,331,682 |
52
Week Range: |
$1.94 - $5.59 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
3,439,830 |
4,023,225 |
Total Buy Value |
$0 |
$0 |
$10,277,564 |
$11,106,809 |
Total People Bought |
0 |
0 |
12 |
12 |
Total Buy Transactions |
0 |
0 |
14 |
42 |
Total Shares Sold |
0 |
187,843 |
187,843 |
187,843 |
Total Sell Value |
$0 |
$885,322 |
$885,322 |
$885,322 |
Total People Sold |
0 |
3 |
3 |
3 |
Total Sell Transactions |
0 |
3 |
3 |
3 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hawkins Richard J |
Director |
|
2022-12-07 |
4 |
OE |
$0.65 |
$762 |
D/D |
1,172 |
1,900 |
|
- |
|
Pratt Raymond Dennis |
Chief Medical Officer |
|
2022-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
Ramsay David A |
Director |
|
2022-11-21 |
4 |
B |
$1.42 |
$35,532 |
D/D |
25,005 |
1,926,147 |
2.39 |
20% |
|
Ramsay David A |
Director |
|
2022-11-18 |
4 |
B |
$1.34 |
$21,606 |
D/D |
16,100 |
1,901,142 |
2.39 |
34% |
|
Ramsay David A |
Director |
|
2022-11-17 |
4 |
B |
$1.27 |
$11,303 |
D/D |
8,900 |
1,885,042 |
2.39 |
49% |
|
Ramsay David A |
Director |
|
2022-09-27 |
4 |
B |
$1.37 |
$101,381 |
D/D |
73,893 |
1,876,142 |
2.39 |
66% |
|
Ramsay David A |
Director |
|
2022-09-26 |
4 |
B |
$1.38 |
$43,052 |
D/D |
31,107 |
1,802,249 |
2.39 |
75% |
|
Ramsay David A |
Director |
|
2022-09-23 |
4 |
B |
$1.42 |
$42,660 |
D/D |
30,000 |
1,771,142 |
2.39 |
71% |
|
Ramsay David A |
Director |
|
2022-09-20 |
4 |
B |
$1.45 |
$870 |
D/D |
600 |
1,741,142 |
2.31 |
64% |
|
Ramsay David A |
Director |
|
2022-09-19 |
4 |
B |
$1.46 |
$2,040 |
D/D |
1,400 |
1,740,542 |
2.31 |
73% |
|
Ramsay David A |
Director |
|
2022-09-16 |
4 |
B |
$1.44 |
$8,652 |
D/D |
6,000 |
1,739,142 |
2.39 |
76% |
|
Ramsay David A |
Director |
|
2022-09-08 |
4 |
B |
$1.40 |
$40,571 |
D/D |
29,000 |
1,733,142 |
2.39 |
46% |
|
Ramsay David A |
Director |
|
2022-09-07 |
4 |
B |
$1.39 |
$2,950 |
D/D |
2,130 |
1,704,142 |
2.31 |
45% |
|
Ramsay David A |
Director |
|
2022-09-06 |
4 |
B |
$1.38 |
$1,201 |
D/D |
870 |
1,702,012 |
2.31 |
38% |
|
Ramsay David A |
Director |
|
2022-09-01 |
4 |
B |
$1.42 |
$56,471 |
D/D |
39,768 |
1,701,142 |
2.39 |
30% |
|
Ramsay David A |
Director |
|
2022-08-31 |
4 |
B |
$1.42 |
$56,200 |
D/D |
39,494 |
1,661,374 |
2.39 |
26% |
|
Ramsay David A |
Director |
|
2022-08-30 |
4 |
B |
$1.41 |
$29,261 |
D/D |
20,738 |
1,621,880 |
2.39 |
27% |
|
Ramsay David A |
Director |
|
2022-06-22 |
4 |
B |
$1.45 |
$56,355 |
D/D |
39,000 |
1,601,142 |
2.39 |
-21% |
|
Ramsay David A |
Director |
|
2022-06-21 |
4 |
B |
$1.38 |
$29,110 |
D/D |
21,094 |
1,562,142 |
2.39 |
-13% |
|
Ramsay David A |
Director |
|
2022-06-17 |
4 |
B |
$1.33 |
$52,915 |
D/D |
39,906 |
1,541,048 |
2.39 |
-5% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2021-12-31 |
4 |
D |
$1.24 |
$77,274 |
D/D |
(62,318) |
721,354 |
|
- |
|
Ramsay David A |
Director |
|
2021-12-30 |
4 |
B |
$1.30 |
$45,360 |
D/D |
35,000 |
1,501,142 |
2.39 |
-15% |
|
Ramsay David A |
Director |
|
2021-12-29 |
4 |
B |
$1.25 |
$18,675 |
D/D |
15,000 |
1,466,142 |
2.39 |
-10% |
|
Ramsay David A |
Director |
|
2021-12-17 |
4 |
B |
$1.13 |
$28,225 |
D/D |
25,000 |
1,451,142 |
2.39 |
- |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2021-12-17 |
4 |
B |
$1.14 |
$4,569 |
D/D |
4,000 |
142,793 |
2.66 |
- |
|
239 Records found
|
|
Page 3 of 10 |
|
|